Loading…
← CockpitCompetitor Analysis › 301234.SZ Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd. Class AOpen in the cockpit ↗

Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd. Class A301234.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 100
Mkt cap
$697M
US dollars, full cap
$/day
$37.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+4.1 pp
WACC 5.0%
Hurdle
+32 pp
Req g minus delivered
Close · CNYCN¥101.10
1D-2.7%
1W-8.1%
1M-23.9%
3M+11.6%
6M+148.0%
YTD+137.9%
1Y+130.6%
ATR %11.8%
52w lowhigh35.8% off high

What Anhui Hongyu Wuzhou Medical Manufacturer does

Employees: 856

Anhui Hongyu Wuzhou Medical Manufacturer at a glance

Size Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ) is a China Health Care company (Medical Specialties) with a market value of $697M, the 2907th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥101.10 on 18 Nov 2026.

Performance Over six months the shares gained 148.0%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue fell 14.0% over the last twelve months (peer median +14.8%); the operating margin is 3.2% (peer median 13.7%).

Valuation It trades at 10.3× enterprise value to sales against a peer median of 3.0× (2nd most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.1 points above its cost of capital (5.0% WACC).

Relative performance

10020030040021 May 202621 Aug 202618 Nov 2026301234.SZ 250Peer median 86
Six months, rebased to 100: Anhui Hongyu Wuzhou Medical Manufacturer against the median of its 20 peers (local-currency closes).

Anhui Hongyu Wuzhou Medical Manufacturer financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥413MCN¥457MCN¥476MCN¥533MCN¥546M
Revenue growth—-4%-11%-2%—
Gross profitCN¥95.7MCN¥61.4MCN¥79.9MCN¥109MCN¥119M
EBITDAn/aCN¥54.3MCN¥69.1MCN¥86.6MCN¥77.2M
Net incomeCN¥17.9MCN¥18.9MCN¥40.0MCN¥60.3MCN¥70.9M
Free cash flowCN¥14.4MCN¥59.1MCN¥53.7M-CN¥18.9M-CN¥53.0M
Capital expenditureCN¥36.9MCN¥19.8MCN¥37.0MCN¥70.9MCN¥164M
Total debtCN¥495,568CN¥680,413CN¥1.95MCN¥782,956CN¥849,303

Quarterly statements and history in the cockpit →

Anhui Hongyu Wuzhou Medical Manufacturer competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%15016880857575688389688410491000300622DCTH301122300326SNT688179301367600855QDELINMD603108300453002950301234.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Anhui Hongyu Wuzhou Medical Manufacturer is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%5×10×15016880857575688389688410491000300622DCTH002876301122300326SNT688179301367600855QDELINMD603108002950301234.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Anhui Hongyu Wuzhou Medical Manufacturer is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%15016880857575688389688410300622DCTH300326SNT688179INMD603108301234.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Anhui Hongyu Wuzhou Medical Manufacturer is the large dot.

Anhui Hongyu Wuzhou Medical Manufacturer competitors and peer comparison

How Anhui Hongyu Wuzhou Medical Manufacturer compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anhui Hongyu Wuzhou Medical Manufacturer against its 20 peers (data as of 18 Nov 2026)
Measure301234.SZPeer medianRank in peer set
1-month return-23.9%-7.3%3rd lowest of 21
6-month return+148.0%-15.1%highest of 21
Distance from 52-week high-35.8%-38.0%11th highest of 21
Revenue growth (TTM)-14.0%+14.8%2nd lowest of 21
Operating margin3.2%13.7%6th lowest of 21
EV / Sales10.3×3.0×2nd most expensive of 21
Growth the price implies (Req g, 7 yrs)31.8%6.6%2nd most demanding of 16
Growth delivered (Del g)-0.6%+14.2%2nd lowest of 16
Hurdle (Req g minus delivered)+32.5 pp-12.4 ppmost demanding of 16
ROIC minus cost of capital+4.1 pp+2.3 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%10.3×31.8%-0.6%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%3.6×-3.3%+23.5%
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%7.1×29.0%+6.8%
Japan Lifeline 7575.TJapan$703M+34%+6%19%1.7×-9.5%+2.9%
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%3.0×11.6%+13.3%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%3.6×16.2%+25.9%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%18.1×n/an/a
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%3.1×-3.4%+15.7%
Delcath Systems DCTHUnited States$685M+75%+38%5%5.3×33.4%+120.2%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%1.6×10.1%+14.2%
Caina Technology 301122.SZChina$721M+36%+61%0%7.7×n/an/a
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%3.8×6.6%-1.9%
Synektik SNT.WAPoland$662M+10%+32%24%2.9×0.2%+47.5%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%5.8×17.1%+24.2%
BMC Medical 301367.SZChina$737M-17%+37%17%1.8×-1.5%+15.6%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%4.5×n/an/a
QuidelOrtho QDELUnited States$657M-20%-5%-2%1.4×n/an/a
InMode INMDUnited States$741M-8%+2%18%0.6×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%1.7×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%2.8×-1.9%+11.8%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%1.5×n/an/a

Questions

Which companies are Anhui Hongyu Wuzhou Medical Manufacturer's closest peers?
The cockpit's peer set: Shanghai INT Medical Instruments (1501.HK), Shanghai Sanyou Medical (688085.SS), Japan Lifeline (7575.T), Shenzhen Lifotronic Technology (688389.SS), SWS Hemodialysis Care (688410.SS), Livsmed (491000.KS), Doctorglasses Chain (300622.SZ), Delcath Systems (DCTH).
Is Anhui Hongyu Wuzhou Medical Manufacturer expensive compared with its peers?
On ev / sales it trades at 10.3× against a peer median of 3.0×, 2nd most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Anhui Hongyu Wuzhou Medical Manufacturer stock performed?
Over six months to 18 Nov 2026 the shares returned +148.0% against -15.1% for the median peer; over one year +130.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.